Pacira BioSciences Reports First Quarter 2021 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Pacira Pharma (PCRX) Misses Q1 EPS by 7c
May 4, 2021 8:03 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.56, $0.07 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $119 million versus the consensus estimate of $119.28 million.
First Quarter 2021 Financial Results
Total revenues were $119.0 million in the first quarter of 2021, versus $105.7 million reported for the first quarter of 2020.EXPAREL net product sales were $114.7 million in the first quarter of 2021, versus $101.3 million reported for the first quarter of 2020.First quarter 2021 iovera° net product sales were $3.3 million, versus $2.3 million reported for the first quarter of 2020.Sales of bupivacaine liposome injectable... More